The Medicines Company
| The Medicines Company | |
|---|---|
| legal form | Incorporated |
| ISIN | US5846881051 |
| founding | 1996 |
| Seat | Parsippany , United States |
| management | Clive Meanwell, Chairman and CEO |
| Number of employees | 62 |
| sales | 6.138 million USD |
| Branch | pharmacy |
| Website | www.themedicinescompany.com |
| As of December 31, 2018 | |
The pharmaceutical company The Medicines Company was founded in 1996 and is traded on the New York Stock Exchange ( NASDAQ ) under the symbol "MDCO". The Medicines Company is primarily active in intensive care medicine in the hospital market . Worldwide sales were $ 687.9 million in 2013. In November 2019, the company announced an agreement to acquire Novartis for $ 9.7 billion.
Therapy / research areas
The Medicines Company works and researches in the therapeutic areas of intensive care medicine ( anticoagulants and antibiotics ).
- Bivalirudin (tradename in the US Angiomax ® , in the EU Angiox ® ) is a direct thrombin - inhibitor , which is used to clot to prevent in adults undergoing percutaneous undergo coronary intervention (PCI). The drug is approved in both the US and the EU. It is the company's main product.
- Clevidipin (trade name Cleviprex ® ) is a calcium antagonist for the rapid reduction of blood pressure in perioperative situations. The substance was approved in the USA in 2008 and in Switzerland in 2010. Approval is still pending in the EU.
- Argatroban (trade name Argatra ® ) is a medicinal substance that inhibits blood clotting . The synthetic direct inhibitor of thrombin has been approved in Germany and Austria since 2005 under the name Argatra ® for anticoagulation in adults with heparin-induced thrombocytopenia of type II (HIT II), if they require parenteral antithrombotic therapy. In Germany, Argatroban is distributed by Mitsubishi Pharma Deutschland GmbH .
pipeline
Cangrelor is an intravenous direct P2Y12 receptor antagonist and an experimental drug used to inhibit blood clotting. Cangrelor is still in the approval process.
International / Germany
The Medicines Company operates in the United States, Europe, the Middle East, and the Asia-Pacific region. Global headquarters are in Parsippany, New Jersey, USA and in Zurich, Switzerland. The German branch is located in Munich .
Web links
Individual evidence
- ^ A b c The Medicines Company: About Us. ( Memento from February 23, 2014 in the Internet Archive )
- ↑ a b Annual Report 2018 (Form 10-K Report) (pdf), accessed on November 25, 2019 (English)
- ^ A b c The Medicines Company: The Medicines Company Reports Fourth Quarter and Full Year 2013 Financial Results. 2014, accessed March 15, 2014 .
- ^ The Medicines Company Enters Into Definitive Agreement to be Acquired by Novartis AG for $ 9.7 billion. In: www.themedicinescompany.com. November 24, 2019, accessed November 25, 2019 .
- ↑ Summary of the EPAR for the public (German) , website of the European Health Authority (EMA), accessed on March 15, 2014 (PDF; 80 kB)
- ↑ The Medicines Company's Cleviprex (TM) Receives FDA Approval , PM of the manufacturer August 4, 2008, accessed March 15, 2014.
- ↑ Cleviprex - Swissmedic-Registration , website of ODDB.org, accessed on March 15, 2014.
- ^ New on the market , Pharmazeutische Zeitung Online, accessed March 15, 2014.
- ↑ www.argatra.de , Mitsubishi Pharma Germany product website, accessed on March 15, 2014.
- ↑ Product development is innovation. ( January 7, 2015 memento on the Internet Archive ) The Medicines Company website, accessed March 29, 2014.
- ↑ The Medicines Company Receives Complete Response Letter From FDA Requesting Additional Information for New Drug Application for Its Antiplatelet Agent Cangrelor , PM of The Medicines Company, April 30, 2014, accessed May 2, 2014.
- ^ The Medicines Company: Global Locations. (No longer available online.) 2014, archived from the original on March 16, 2014 ; accessed on March 15, 2014 .
- ^ The Medicines Company: Germany. (No longer available online.) 2014, archived from the original on March 15, 2014 ; accessed on March 15, 2014 .